Drug Development
After years of contraction, investors see biotech reentering a growth cycle driven by scientific progress, asset quality and renewed conviction in oncology, obesity and neuroscience innovation.
FEATURED STORIES
Together with robust data-driven modeling, rethinking regulation and data use could push forward a notoriously challenging field.
From opening new therapeutic mechanisms to repairing neuronal damage, investigational molecules from Ventyx Therapeutics, AC Immune, Gain Therapeutics and more could shape the future of Parkinson’s disease treatment.
As drug candidates discovered via AI move into later-stage clinical trials, the technology seems to be doing as promised: speeding drug development.
Subscribe to ClinicaSpace
Clinical trial results, research news, the latest in cancer and cell and gene therapy, in your inbox every Monday
THE LATEST
Kymera was able to demonstrate for the first time proof-of-biology ex vivo using whole blood from one of their KT-474 treated patient cohorts.
Despite these challenges, Raphael remains dedicated to developing the field of cancer metabolism-based therapeutics.
AbbVie’s experimental subcutaneous Parkinson’s disease drug ABBV-951 hit the mark in a 12-week Phase III study in patients with an advanced form of the disease.
Emergent BioSolutions, the manufacturer responsible for the doses in question, is reportedly just waiting for the U.S. FDA’s signal to start shipping the vaccines.
Researchers believe the drug PUL-042 may work against COVID-19 and other respiratory infections, including all existing and future variants of SARS-CoV-2.
The letter was related to a 2021 FDA inspection connected to Sesen’s Biologics License Application for Vicineum. Read more about this sesen bio news here.
The 643-participant study failed to reach statistical significance in its co-primary cognitive and functional endpoints, ADAS-Cog11 and ADCS-ADL, at end of treatment.
The deal was struck one month after GammaDelta dosed its first patient in a Phase I acute myeloid leukemia (AML) trial.
A large number of people were waiting for the breast cancer vaccine. Now, at present, the world has witnessed the first potential vaccine. Let’s take a look at it.
Teva Pharmaceuticals inked a deal with MODAG GmbH to license and develop two of MODAG’s compounds in neurodegenerative disease, anle138b and sery433.